Why is RA Difficult to Treat? Dr. Jonathan Kay shares his perspective on five posters presented at EULAR 2025 in Barce

Social Author Image
https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Why is RA Difficult to Treat? Dr. Jonathan Kay shares his perspective on five posters presented at EULAR 2025 in Barcelona, Spain. Posters reviewed: POS0027, POS0028, POS0185, POS0030, POS0163 https://t.co/Ad4hVN21MJ https://t.co/d0BfQWjjL0
Links
Why is RA Difficult to Treat? | RheumNow https://buff.ly/V5mVlNn

FDA has approved a SC autoinjector of Benlysta (BEL) for use in pediatric lupus nephritis & pts > 5rs of age for

Social Author Image
https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
FDA has approved a SC autoinjector of Benlysta (BEL) for use in pediatric lupus nephritis & pts > 5rs of age for SLE and active LN. BEL SC dosing for Pediatric SLE: 200 mg qwk (>40 kg) or 200 mg EOW (q2wk) if 15-40 kg. https://t.co/xrMJUgdSWv https://t.co/UJ2LZ3dU5p
Links
FDA Approves Belimumab (Benlysta) Autoinjector for Pediatric Lupus Nephritis https://buff.ly/1E4tUiL

Difficult to Treat Psoriatic Arthritis Dr. Eric Ruderman shares his perspectives on data being presented at the 2025 E

Social Author Image
https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Difficult to Treat Psoriatic Arthritis Dr. Eric Ruderman shares his perspectives on data being presented at the 2025 EULAR meeting in Barcelona, Spain. https://t.co/AdKILLc12Y https://t.co/4pB0OH2Gup
Links
Difficult to Treat Psoriatic Arthritis | RheumNow https://buff.ly/S6AXvF7

GLP 1 Receptor Agonists in axSpA

The Spectrum of RA

ADD THE FIRST COMMENT

Rituximab - Super Responders Exist in SLE

24 June 2025
GRAPPA vs. EULAR on Complex/Difficult-to-Manage Psoriatic Arthritis
The “Difficult” framework has now reached PsA. At EULAR 2025, two independent definitions were presented: one by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and another by EULAR. This short review explores the similarities and differences between these definitions and discusses their potential implications for clinical practice and research, especially for the increasingly perplexed rheumatologist.

IL-17 Inhibitors for Axial Spondyloarthritis

Full read overview of MDA-5 Dermatomyositis (DM) - pathogenesis, findings, & Rx. MDA-5 DM is a rare, aggressive amyo

Social Author Image
https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Full read overview of MDA-5 Dermatomyositis (DM) - pathogenesis, findings, & Rx. MDA-5 DM is a rare, aggressive amyopathic form with distinctive skin findings & rapidly progressive interstitial lung dz. Rx includes Hi dose steroids, calcineurin inhib & IV CTX (maybe JAKi, MMF)
23 June 2025
Simple Measures are Effective in Knee Osteoarthritis

Knee braces, water therapy and exercise are the most promising non-drug therapies for treating knee osteoarthritis, according to a new meta-analysis publishing June 18, 2025 in the open-access journal PLOS One by Yuan Luo of the First People’s Hospital of Neijiang, China.

Knee osteoarthritis (KOA) is a common and often debilitating condition that affects millions of older adults, causing pain and stiffening of the knee joint. Treatment often includes anti-inflammatory drugs, which are linked to gastrointestinal and cardiovascular adverse events.

Subscribe to
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×